Harvard Bioscience Board Unanimously Rejects Skystone's Offer

Harvard Bioscience, Inc., a leading provider of tools to advance life science research, confirmed that its board of directors had unanimously rejected an unsolicited written offer from Skystone Advisors LLC to acquire all outstanding shares of common stock not already owned by Skystone and its affiliates for $5.00 per share.
BioSpace